Drug-delivering endovascular treatment versus angioplasty in artery occlusion diseases: a systematic review and meta-analysis.
This study aimed to compare the efficacy of drug-coated balloons (DCB) and drug-eluting stents (DES) with percutaneous transluminal angioplasty (PTA) in patients with femoropopliteal or infrapopliteal arterial occlusive disease. METHODS: Medline, Cochrane, EMBASE, and Google Scholar databases were searched for randomized controlled trials from January 1, 2000 until June 30, 2016. RESULTS: Compared with PTA, significant benefits in favor of DCB and DES were found for target lesion revascularization (TLR) (OR = 0.38, 95%CI = 0.22 to 0.66, P = 0.001 for DCB; OR = 0.51, 95% CI = 0.32 to 0.81, P
ConclusionEndovascular procedures can be safe and provide prompt recovery in early HAT patients following liver transplantation to prevent graft loss and patient mortality despite the presence of hemorrhage and rebound thrombosis. Immediate endovascular procedure after the end of the transplantation is also necessary in intraoperatively developed HAT instead of several trials of arterial anastomoses to revascularization.
Publication date: Available online 22 May 2020Source: European Journal of RadiologyAuthor(s): Nikolaos Galanakis, Thomas G Maris, Nikolaos Kontopodis, Christos V. Ioannou, Konstantinos Tsetis, Apostolos Karantanas, Dimitrios Tsetis
Condition: Peripheral Artery Disease Intervention: Device: AcoArt Orchid (0.035 " ), AcoArt Tulip (0.018 " ) and AcoArt Litos (0.014 " ) percutaneous transluminal angioplasty (PTA) paclitaxel drug coated balloon catheter manufactured by Acotec Scientific Co., Ltd. Sponsor: Acotec Scientific Co., Ltd Not yet recruiting
th M Abstract Giant cell arteritis (GCA) and Takayasu's arteritis (TAK) both belong to the group of large vessel vasculitides and require long-term drug treatment. Glucocorticoids (GC) are the first choice for the treatment of both diseases. For GCA immunosuppressants, such as tocilizumab or methotrexate should be considered in cases of treatment refractory and relapses or if there is a high risk for GC-related adverse events. In TAK patients the use of immunosuppressive agents should be considered for all patients. In the course of the disease, severe disease-associated and treatment-associated complications...
To evaluate the outcome of percutaneous transluminal angioplasty (PTA) in patients with critical limb ischemia (CLI) due to popliteal artery (PA) chronic total occlusion (CTO) depending on the presence of a patent portion of PA distal to the occlusive lesion – the distal landing zone (DLZ).
CONCLUSION: The results of this study indicate that the use of carvedilol for more than 84 days improves the primary patency of AVGs, but the use of carvedilol for less than 84 days does not. PMID: 32408854 [PubMed - as supplied by publisher]
Conclusion: Endovascular treatment of the central vein occlusion using a conventional technique is moderately effective and safe. Angioplasty alone and stenting were not significantly different in terms of patency rate. The age of the patients and type of occlusion were significant predictors for successful recanalization. Published on 2020-05-06 10:45:15
This study, however, had a number of limitations, which have been discussed at great length among the vascular community. The aim of this research was to assess the association between paclitaxel based endovascular treatment (PTX) in the femoropopliteal (F –P) segment and mortality, adjusting for relevant risk factors and including patients with chronic limb threatening ischaemia (CLTI).
CONCLUSION: When relevant risk factors were taken into account, there were no associations between PTX and mid term mortality in patients with PAOD. PMID: 32370918 [PubMed - as supplied by publisher]
Conditions: Headache; Jugular Vein Occlusion Interventions: Device: PTA + Stenting using " Petalo stent " ; Procedure: Percutaneous Transluminal Angioplasty (PTA) Sponsor: University of Catania Not yet recruiting